Adalimumab biosimilar (Amgen)

阿达木单抗生物类似药（安进）

Report date: 2026/03/30 20:02:02

Base Information

Drug NameAdalimumab biosimilar (Amgen)
Drug Alias Name阿达木单抗生物仿制药（安进）Adalimumab-atto - AmgenAdalimumab beta - AmgenAmjevitaAmgevita +[7] 
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionTumor necrosis factor α inhibitors
TargetsTumor necrosis factor α
Therapy Area/IndicationsPlaque psoriasisPediatric ulcerative colitisNon-radiographic axial spondyloarthritis +[15] 
Global Approved IndicationsPlaque psoriasisNon-radiographic axial spondyloarthritisPolyarticular Juvenile Idiopathic Arthritis +[14] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2016/09/23
Country/TerritoryCzechiaBulgariaCanada +[14] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesAmgen Inc
China Registration ClassN/A

Develop Information

Active CompaniesAmgen Europe BvAmgen Inc
Inactive CompaniesN/A
Active IndicationsPlaque psoriasisPediatric ulcerative colitisNon-radiographic axial spondyloarthritis +[15] 
Inactive IndicationsN/A

Other Information

ATC CodeL04AB04
Related LinksWikipedia